These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 2886886)

  • 1. Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release.
    Karashima T; Cai RZ; Schally AV
    Life Sci; 1987 Aug; 41(8):1011-9. PubMed ID: 2886886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of somatostatin and its highly potent hexa- and octapeptide analogs on exocrine and endocrine pancreatic secretion.
    Konturek SJ; Bilski J; Jaworek J; Tasler J; Schally AV
    Proc Soc Exp Biol Med; 1988 Feb; 187(2):241-9. PubMed ID: 2448802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin.
    Cai RZ; Szoke B; Lu R; Fu D; Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1986 Mar; 83(6):1896-900. PubMed ID: 2869490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells.
    Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Lamberts SW
    Endocrinology; 1994 Jan; 134(1):301-6. PubMed ID: 7903931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of somatostatin analogs on prolactin secretion in rats pretreated with estrogen or haloperidol.
    Karashima T; Schally AV
    Proc Soc Exp Biol Med; 1987 May; 185(1):69-75. PubMed ID: 2883661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superactive octapeptide somatostatin analogs containing tryptophan at position 1.
    Cai RZ; Karashima T; Guoth J; Szoke B; Olsen D; Schally AV
    Proc Natl Acad Sci U S A; 1987 Apr; 84(8):2502-6. PubMed ID: 2882520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superactive somatostatin analog decreases plasma glucose and glucagon levels in diabetic rats.
    Karashima T; Schally AV
    Peptides; 1988; 9(3):561-5. PubMed ID: 2901737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Ala-2-D-Trp-8-D-Cys-14-somatostatin on the arginine induced release of insulin, GH and glucagon in normal men.
    Gonzalez-Barcena D; Mendoza F; Medina R; Coy DH; Murphy WA; Schally AV
    Endocr Res; 1984; 10(1):39-48. PubMed ID: 6146518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of somatostatin analogs on gastric acid secretion in dogs and rats.
    Schally AV; Colaluca J; Paulson D; Carter WH; Neitzschman HR; Lafaye H; Cai RZ
    Int J Pept Protein Res; 1990 Sep; 36(3):267-74. PubMed ID: 1980670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin.
    Murphy WA; Lance VA; Moreau S; Moreau JP; Coy DH
    Life Sci; 1987 Jun; 40(26):2515-22. PubMed ID: 2885701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of receptors for somatostatin in various tumors using different analogs.
    Srkalovic G; Cai RZ; Schally AV
    J Clin Endocrinol Metab; 1990 Mar; 70(3):661-9. PubMed ID: 1968467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin: analogs with selected biological activities.
    Brown M; Rivier J; Vale W
    Science; 1977 Jun; 196(4297):1467-9. PubMed ID: 867045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin antagonist analog increases GH, insulin, and glucagon release in the rat.
    Fries JL; Murphy WA; Sueiras-Diaz J; Coy DH
    Peptides; 1982; 3(5):811-4. PubMed ID: 6129618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An in vivo model for testing inhibition of arginine-induced insulin and glucagon release by somatostatin analogs.
    Gordin A; Meyers C; Arimura A; Coy DH; Schally AV
    Acta Endocrinol (Copenh); 1977 Dec; 86(4):833-41. PubMed ID: 335762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent, highly selective inhibition of growth hormone secretion by position 4 somatostatin analogs.
    Murphy WA; Meyers CA; Coy DH
    Endocrinology; 1981 Aug; 109(2):491-5. PubMed ID: 6113951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infusion of graded concentrations of somatostatin in man: pharmacokinetics and differential inhibitory effects on pituitary and islet hormones.
    Skamene A; Patel YC
    Clin Endocrinol (Oxf); 1984 May; 20(5):555-64. PubMed ID: 6146413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of sleep related growth hormone release by Phe-4-somatostatin.
    Cabranes JA; Vela A; Timoneda F; Meyers CA; Coy DH; Schally AV; Charro AL
    Res Commun Chem Pathol Pharmacol; 1984 Sep; 45(3):421-31. PubMed ID: 6150528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of growth hormone and glucagon release by Phe-4-somatostatin in patients with acromegaly.
    Charro AL; Cabranes JA; Lafuente A; Diaz-Salgado C; Cordero M; Almoguera I; Comaru-Schally AM; Meyers CA; Coy DH; Schally AV
    Res Commun Chem Pathol Pharmacol; 1984 Sep; 45(3):432-44. PubMed ID: 6150529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin-28 is longer acting and more selective than somatostatin-14 on pituitary and pancreatic hormone release.
    Tannenbaum GS; Ling N; Brazeau P
    Endocrinology; 1982 Jul; 111(1):101-7. PubMed ID: 6123428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.